Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Nilotinib + ZSTK474 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Nilotinib | Tasigna | AMN-107|AMN107 | ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 28 CSF1R Inhibitor 26 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 52 PDGFR Inhibitor (Pan) 27 | Tasigna (nilotinib) inhibits several tyrosine kinases including BCR-ABL, PDGFR, KIT, DDR and CSF-1R, potentially resulting in reduced tumor cell proliferation (PMID: 21419934, PMID: 25284748). Tasigna (nilotinib) is FDA approved for use in patients with Ph+ (BCR-ABL1) chronic myeloid leukemia (FDA.gov). |
ZSTK474 | ZSTK-474 | PI3K Inhibitor (Pan) 39 | ZSTK474 is a pan-PI3K inhibitor, which blocks PI3K/AKT signaling to prevent cell growth (PMID: 16622124, PMID: 30205797). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|